The Headache Inducing Effects of Cilostazol on Migraine Patients

We will use Cilostazol as a tool to investigate its headache inducing effects in migraine patients.

Completed

Looking for future studies?

Key information

Conditions

Migraine Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Migraine Disorders Nervous System Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Danish Headache Center & Department of Neurology

Copenhagen, Glostrup, 2600, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed with migraine without aura according to the IHS criteria from 2004.
Healthy besides migraine

Exclusion criteria

Tension-type headache more than 3 days per month
Other types of primary headaches
Pregnancy
History of vascular diseases or psychiatric diseases.

Treatment and study plan

Cilostazol

Drug

Other names: Pletal

Placebo

Drug

Primary outcomes

The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo.

Time frame: Outcome measure will be done within 3 month. Final data will be presented within 6 months

Rectruitment of 14 patients will be done during April and May. Experiments will be carried out in May and June. Each experiment day takes 1½ hour. Data analysis will be done in June and July. Final data will be presented within 6 months.

Sponsors and collaborators

Lead sponsor

Danish Headache Center

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2013
Study completion: 2013
First posted: Apr 29, 2013
Registry last updated: Jun 6, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed